Mesoblast Limited (MSB.AX)
AUD 3.05
(54.04%)
AUD 3.05
(54.04%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -57.97 Million USD | 16.33% |
| 2023 | -69.28 Million USD | 14.01% |
| 2022 | -80.57 Million USD | 26.14% |
| 2021 | -109.09 Million USD | -45.71% |
| 2020 | -74.87 Million USD | 6.65% |
| 2019 | -80.2 Million USD | -3.7% |
| 2018 | -77.33 Million USD | 14.11% |
| 2017 | -90.04 Million USD | -61.11% |
| 2016 | -55.88 Million USD | 50.71% |
| 2015 | -113.39 Million USD | -56.67% |
| 2014 | -72.37 Million USD | -20.47% |
| 2013 | -60.07 Million USD | -23.31% |
| 2012 | -48.72 Million USD | -151.96% |
| 2011 | 93.76 Million USD | 1002.7% |
| 2010 | -10.38 Million USD | -10.16% |
| 2009 | -9.42 Million USD | -18.76% |
| 2008 | -7.93 Million USD | -13.2% |
| 2007 | -7.01 Million USD | -11.61% |
| 2006 | -6.28 Million USD | -536.98% |
| 2005 | -986.54 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -13.29 Million USD | 0.0% |
| 2024 Q1 | -13.29 Million USD | 30.33% |
| 2024 FY | -56.14 Million USD | 18.97% |
| 2023 Q3 | -14.46 Million USD | 31.5% |
| 2023 Q4 | -19.07 Million USD | -31.91% |
| 2023 Q1 | -16 Million USD | 19.2% |
| 2023 Q2 | -21.11 Million USD | -31.92% |
| 2023 FY | -69.28 Million USD | 14.01% |
| 2022 Q4 | -19.8 Million USD | -2.41% |
| 2022 Q3 | -19.34 Million USD | 12.96% |
| 2022 Q2 | -22.21 Million USD | -15.68% |
| 2022 FY | -80.57 Million USD | 26.14% |
| 2022 Q1 | -19.2 Million USD | 0.45% |
| 2021 Q4 | -19.29 Million USD | 25.52% |
| 2021 Q2 | -26.31 Million USD | 26.0% |
| 2021 Q1 | -35.55 Million USD | -11.16% |
| 2021 Q3 | -25.9 Million USD | 1.55% |
| 2021 FY | -109.09 Million USD | -45.71% |
| 2020 Q3 | -15.52 Million USD | 34.56% |
| 2020 Q4 | -31.98 Million USD | -106.11% |
| 2020 FY | -74.87 Million USD | 6.65% |
| 2020 Q2 | -23.71 Million USD | -577.21% |
| 2020 Q1 | -3.5 Million USD | 80.04% |
| 2019 Q2 | -24.19 Million USD | -44.18% |
| 2019 FY | -80.2 Million USD | -3.7% |
| 2019 Q3 | -21.68 Million USD | 10.4% |
| 2019 Q4 | -17.54 Million USD | 19.09% |
| 2019 Q1 | -16.78 Million USD | 26.39% |
| 2018 Q3 | -23.6 Million USD | -154.69% |
| 2018 FY | -77.33 Million USD | 14.11% |
| 2018 Q4 | -22.8 Million USD | 3.41% |
| 2018 Q2 | -9.26 Million USD | 53.85% |
| 2018 Q1 | -20.08 Million USD | 13.99% |
| 2017 FY | -90.04 Million USD | -61.11% |
| 2017 Q1 | -21.89 Million USD | -160.51% |
| 2017 Q2 | -22.85 Million USD | -4.39% |
| 2017 Q3 | -21.99 Million USD | 3.75% |
| 2017 Q4 | -23.35 Million USD | -6.17% |
| 2016 FY | -55.88 Million USD | 50.71% |
| 2016 Q1 | -14.46 Million USD | 70.37% |
| 2016 Q2 | -21.79 Million USD | -50.67% |
| 2016 Q4 | 36.17 Million USD | 276.81% |
| 2016 Q3 | -20.46 Million USD | 6.12% |
| 2015 Q3 | -17.25 Million USD | 41.28% |
| 2015 FY | -113.39 Million USD | -56.67% |
| 2015 Q4 | -48.81 Million USD | -182.86% |
| 2015 Q2 | -29.39 Million USD | -77.14% |
| 2015 Q1 | -16.59 Million USD | 10.7% |
| 2014 Q3 | -18.83 Million USD | -1.74% |
| 2014 Q4 | -18.58 Million USD | 1.35% |
| 2014 FY | -72.37 Million USD | -20.47% |
| 2014 Q1 | -10.47 Million USD | 27.11% |
| 2014 Q2 | -18.51 Million USD | -76.69% |
| 2013 Q2 | -14.42 Million USD | -0.06% |
| 2013 Q4 | -14.37 Million USD | 12.05% |
| 2013 Q3 | -16.34 Million USD | -13.31% |
| 2013 FY | -60.07 Million USD | -23.31% |
| 2013 Q1 | -14.41 Million USD | 0.0% |
| 2012 FY | -48.72 Million USD | -151.96% |
| 2011 FY | 93.76 Million USD | 1002.7% |
| 2010 FY | -10.38 Million USD | -10.16% |
| 2009 FY | -9.42 Million USD | -18.76% |
| 2008 FY | -7.93 Million USD | -13.2% |
| 2007 FY | -7.01 Million USD | -11.61% |
| 2006 FY | -6.28 Million USD | -536.98% |
| 2005 FY | -986.54 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 696.631% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -3873.061% |
| Bio-Gene Technology Limited | -3.06 Million AUD | -1792.986% |
| Zelira Therapeutics Limited | -5.93 Million AUD | -876.25% |
| Biome Australia Limited | -1.91 Million AUD | -2930.043% |
| Patrys Limited | -3.53 Million AUD | -1538.02% |
| Orthocell Limited | -11.68 Million AUD | -396.288% |
| Imugene Limited | -140.93 Million AUD | 58.865% |
| Noxopharm Limited | -7.53 Million AUD | -669.369% |
| PYC Therapeutics Limited | -38.85 Million AUD | -49.192% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | -370.947% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -706.688% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | -701.654% |
| Cynata Therapeutics Limited | -8.8 Million AUD | -558.18% |
| CSL Limited | 5.64 Billion AUD | 101.026% |
| Arovella Therapeutics Limited | -7.19 Million AUD | -705.945% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | -294.371% |
| Race Oncology Limited | -13.38 Million AUD | -333.255% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 217.954% |
| Starpharma Holdings Limited | -15.15 Million AUD | -282.426% |
| Nanollose Limited | -1.24 Million AUD | -4538.409% |
| Memphasys Limited | -2.7 Million AUD | -2043.935% |
| Invex Therapeutics Ltd | -2.13 Million AUD | -2617.063% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -2718.882% |
| Amplia Therapeutics Limited | -4.42 Million AUD | -1210.11% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | -1917.273% |
| Nyrada Inc. | -4.56 Million AUD | -1171.224% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | -29.4% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Dimerix Limited | -25.05 Million AUD | -131.335% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 125.656% |
| PharmAust Limited | -6.65 Million AUD | -770.63% |
| Immutep Limited | -44.93 Million AUD | -29.007% |
| BTC Health Limited | 1.05 Million AUD | 5593.482% |
| Acrux Limited | -9.83 Million AUD | -489.506% |
| Alterity Therapeutics Limited | -19.6 Million AUD | -195.75% |
| Biotron Limited | -5.15 Million AUD | -1025.414% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | -22.796% |
| Tissue Repair Ltd | -4.87 Million AUD | -1088.937% |
| AdAlta Limited | -5.26 Million AUD | -1001.796% |
| Hexima Limited | -1 Million AUD | -5646.914% |
| AnteoTech Limited | -11.72 Million AUD | -394.363% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 10.966% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | -162.897% |
| Avecho Biotechnology Limited | -4.58 Million AUD | -1163.23% |
| Actinogen Medical Limited | -12.83 Million AUD | -351.531% |
| Immuron Limited | -5.8 Million AUD | -899.325% |
| Argenica Therapeutics Limited | -5.67 Million AUD | -922.217% |